High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Han, Ju ^a   Yong, Bicheng ^a   Luo, Canqiao ^a   Tan, Pingxian ^a   Peng, Tingsheng ^a   Shen, Jingnan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

ALP; Metastasis; MMP 9; Osteosarcoma; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; GELATINASE B; TUMOR MARKER;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHINA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SCHOOL CHILD; BLOOD; BONE TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BONE NEOPLASMS; CHILD; CHINA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856998743     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-37     Document Type: Article

References (32)

1. Ham SJ, Schraffordt KH, van der Graaf WT, van Horn JR, Postma L, Hoekstra HJ. Historical, current and future aspects of osteosarcoma treatment. Eur J Surg Oncol 1998, 24:584-600. 10.1016/S0748-7983(98)93896-3, 9870738.
2. Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, Zhao H, Yao Y. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol 2011, 28:649-653. 10.1007/s12032-010-9493-4, 20349215.
3. Lee JA, Kim MS, Kim DH, Lim JS, Yoo JY, Koh JS, Lee SY, Jeon DG, Park KD. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 2008, 50:195-200. 10.1002/pbc.21446, 18061933.
4. Yang JL, Yang D, Cogdell D, Du XL, Li HX, Pang Y, Sun Y, Hu LM, Sun BC, Trent J, Chen K, Zhang W. APEX1 Gene Amplification and Its Protein Overexpression in Osteosarcoma: Correlation with Recurrence, Metastasis, and Survival. Technol Cancer Res Treat 2010, 9:161-169.
5. Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W. Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma. Adv Med Sci 2010, 55:266-272. 10.2478/v10039-010-0043-2, 21084254.
6. Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W. [A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis]. Pol Merkur Lekarski 2010, 29:19-26.
7. Bacci G, Picci P, Ferrari S, Orlandi M, Ruggieri P, Casadei R, Ferraro A, Biagini R, Battistini A. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993, 71:1224-1230. 10.1002/1097-0142(19930215)71:4<1224::AID-CNCR2820710409>3.0.CO;2-M, 8435797.
8. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790. 10.1200/JCO.20.3.776, 11821461.
9. Pochanugool L, Subhadharaphandou T, Dhanachai M, Hathirat P, Sangthawan D, Pirabul R, Onsanit S, Pornpipatpong N. Prognostic factors among 130 patients with osteosarcoma. Clin Orthop Relat Res 1997, 206-214.
10. Ehrhart N, Dernell WS, Hoffmann WE, Weigel RM, Powers BE, Withrow SJ. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 1998, 213:1002-1006.
11. Hsieh MY, Hung GY, Yen HJ, Chen WM, Chen TH. Osteosarcoma in preadolescent patients: experience in a single institute in Taiwan. J Chin Med Assoc 2009, 72:455-461. 10.1016/S1726-4901(09)70407-1, 19762312.
12. Peng TS, Qiu JS, Wu HX, Liang HZ, Luo CQ. [Expressions of CD44s, MMP-9, and Ki-67: possible association with invasion, metastasis, and recurrence of osteosarcoma]. Ai Zheng 2002, 21:745-750.
13. Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Kleinerman ES, Schmid-Alliana A, Schmid-Antomarchi H. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 2009, 125:2586-2594. 10.1002/ijc.24665, 2772145, 19544560.
14. Wang Q, Diao X, Sun J, Chen Z. Regulation of VEGF, MMP-9, and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 2011, 35:897-904. 10.1042/CBI20100744, 21306303.
15. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000, 11:281-294. 10.1007/s001980070116, 10928217.
16. Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M, He J. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. J Surg Oncol 2011, 104:841-846. 10.1002/jso.22001, 21721010.
17. Jensen SA, Vainer B, Bartels A, Brunner N, Sorensen JB. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells--associations with histopathology and patients outcome. Eur J Cancer 2010, 46:3233-3242. 10.1016/j.ejca.2010.07.046, 20801641.
18. Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP, Grimer RJ. Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. Eur J Cancer 2005, 41:2846-2852. 10.1016/j.ejca.2005.07.024, 16274987.
19. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here?. Paediatr Drugs 2008, 10:315-327. 10.2165/00148581-200810050-00005, 18754698.
20. Levine AM, Rosenberg SA. Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. Cancer 1979, 44:2291-2293. 10.1002/1097-0142(197912)44:6<2291::AID-CNCR2820440643>3.0.CO;2-S, 292511.
21. Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 1979, 43:2178-2181. 10.1002/1097-0142(197906)43:6<2178::AID-CNCR2820430603>3.0.CO;2-9, 287547.
22. Ford S, Saithna A, Grimer RJ, Picci P. Comparison of the outcome of conventional osteosarcoma at two specialist international orthopaedic oncology centres. Sarcoma 2004, 8:13-18. 10.1080/13577140410001679202, 2395601, 18521388.
23. Liu J, Guo W, Yang RL, Tang XD, Yang Y. [Prognostic factors for 72 patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy]. Zhonghua Wai Ke Za Zhi 2008, 46:1166-1170.
24. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN, Zheng SE. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009, 21:229-235.
25. Yang L, Grey V. Pediatric reference intervals for bone markers. Clin Biochem 2006, 39:561-568. 10.1016/j.clinbiochem.2005.11.015, 16423337.
26. Wang J, Pei F, Tu C, Zhang H, Qiu X. Serum bone turnover markers in patients with primary bone tumors. Oncology 2007, 72:338-342. 10.1159/000113063, 18187955.
27. Rech A, Castro CJ, Mattei J, Gregianin L, Di Leone L, David A, Rivero LF, Tarrago R, Abreu A, Brunetto AL. [Clinical features in osteosarcoma and prognostic implications]. J Pediatr (Rio J) 2004, 80:65-70.
28. Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kroger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab 1999, 84:3174-3181. 10.1210/jc.84.9.3174, 10487683.
29. Zhang Q, Niu XH, Cai YB, Hao L, Ding Y. [Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy]. Zhonghua Wai Ke Za Zhi 2007, 45:1114-1117.
30. Burlina A, Rubin D, Secchiero S, Sciacovelli L, Zaninotto M, Plebani M. Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin Chim Acta 1994, 226:151-158. 10.1016/0009-8981(94)90212-7, 7923810.
31. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000, 88:2952-2960. 10.1002/1097-0142(20000615)88:12+<2952::AID-CNCR11>3.0.CO;2-M, 10898339.
32. Saeter G, Elomaa I, Wahlqvist Y, Alvegard TA, Wiebe T, Monge O, Forrestier E, Solheim OP. Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 1997, 273:156-160.